Lantheus Holdings (LNTH) Non Operating Investment Income (2024 - 2026)
Lantheus Holdings' (LNTH) quarterly Non Operating Investment Income came in at $14.9 million in Q1 2026, up 200.29% year-on-year from $5.0 million in Q1 2025, and up 257.09% on a QoQ basis from -$9.5 million in Q4 2025.
Lantheus Holdings (LNTH) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 3 years of Non Operating Investment Income data on file, last reported at $14.9 million in Q1 2026.
- On a quarterly basis, Non Operating Investment Income rose 200.29% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $21.2 million, a 117.75% increase from a year earlier, with the FY2025 full-year figure at -$8.6 million, up 80.22% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at $14.9 million, up from -$9.5 million in the prior quarter.
- Over the last five years, Non Operating Investment Income for LNTH reached as high as $60.7 million in Q1 2024 and fell as low as -$119.1 million in Q4 2024.
- Historically, Non Operating Investment Income has averaged -$4.1 million across 3 years, with a median of $1.2 million in 2025.
- Across the five-year window, Non Operating Investment Income sank 124.48% in 2025 and soared 200.29% in 2026, its largest moves.
- Year by year, Non Operating Investment Income stood at -$119.1 million in 2024, then surged by 92.03% to -$9.5 million in 2025, then soared by 257.09% to $14.9 million in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were $14.9 million in Q1 2026, -$9.5 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Lantheus Holdings | 7.04 Bn | 6.54 Bn | 230.92 Mn | 14.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.91 Mn |
| Mar 31, 2026 | 14.91 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Mar 31, 2025 | -14.86 Mn |
| Mar 31, 2025 | -14.86 Mn |
| Dec 31, 2024 | -119.06 Mn |
| Dec 31, 2024 | -119.06 Mn |
| Sep 30, 2024 | 37.33 Mn |
| Sep 30, 2024 | 37.33 Mn |
| Jun 30, 2024 | -22.54 Mn |
| Jun 30, 2024 | -22.54 Mn |
| Mar 31, 2024 | 60.70 Mn |
| Mar 31, 2024 | 60.70 Mn |